Efficacy and Safety of 0.05% Halometasone/1% Triclosan Cream Versus 0.1% Mometasone Furoate Cream in the Treatment of truncal vitiligo: A Retrospective Study

Abstract

Objective:To retrospectively evaluate efficacy and safety of 0.05% halometasone/1% triclosan cream (Hal/TCS) in treating truncal vitiligo of children and adolescents.Methods:We retrospectively reviewed the records of children and adolescents with truncal vitiligo treated only with topical Hal/TCS twice daily or only with topical 0.1% mometasone furoate cream (mometasone) twice daily for at least 3 months, and collected relevant data. Efficacy outcomes included patients’ mean repigmentation score after 1- and 3-month treatment calculated based on patients’ repigmentation percentage, and effective rate (percentage of patients with ≥50% repigmentation). Subgroup analyses of patients’ mean repigmentation score based on their age, vitiligo stage, and duration were conducted. Rate of adverse events were calculated.Results:One hundred and twenty-two eligible patients were included, among them, 63 and 59 patients were in the Hal/TCS group and the mometasone group, respectively. After 3 months of treatment, the Hal/TCS group had significantly higher mean repigmentation score and effective rate than the mometasone group (53.49 ± 28.33 vs. 41.46 ± 27.16, P = 0.02; 53.97% vs. 35.59%, P = 0.04, respectively). Patients with shorter disease duration (≤12 months) and patients with progressive vitiligo responded significantly better to the Hal/TCS treatment than patients with longer disease duration and patients with stable vitiligo, respectively. Both treatments were well tolerated and the two treatment groups had comparable rates of adverse events.Conclusions:Short-term Hal/TCS treatment was effective, well-tolerated, and safe in treating vitiligo in the trunk of children and adolescents.